The Valley Desk

Clinical trial reportLung cancer (Amsterdam, Netherlands)Published

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Lung cancer (Amsterdam, Netherlands)
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Carboplatin; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Bispecific; Mutagenesis, Insertional; Mutation; Exons; Adult; Aged; Middle Aged
PubMed ID
41671628
Added to directory
Source checked

Report a correction or request removal